Cellectis (CLLS) Receivables (2013 - 2026)
Cellectis (CLLS) posted quarterly Receivables of $12.7 million for Q1 2026, down 44.56% year-over-year from $23.0 million in Q1 2025, and down 42.58% quarter-over-quarter from $22.2 million in Q4 2025.
Cellectis (CLLS) Receivables (2013 - 2026) Analysis & Trends
Cellectis' Receivables history runs 14 years deep, the most recent figure standing at $12.7 million for Q1 2026.
- In Q1 2026, Receivables fell 44.56% year-over-year to $12.7 million; the TTM figure through Mar 2026 stood at $12.7 million (down 44.56% YoY), while the FY2025 annual figure was $22.2 million, up 4.53% from the prior year.
- Receivables for Q1 2026 stood at $12.7 million, down from $22.2 million in the prior quarter.
- The five-year high for Receivables was $39.1 million in Q1 2024, with the low at $12.7 million in Q1 2026.
- The 5-year median for Receivables is $21.5 million (2023), against an average of $22.1 million.
- The sharpest annual moves came in 2022 and 2024: Receivables sank 48.52% in 2022, then soared 102.1% in 2024.
- Cellectis' Receivables stood at $15.3 million in 2022, then soared by 40.61% to $21.5 million in 2023, then retreated by 1.09% to $21.2 million in 2024, then rose by 4.53% to $22.2 million in 2025, then slumped by 42.58% to $12.7 million in 2026.
- Business Quant data shows CLLS's Receivables at $12.7 million in Q1 2026, $22.2 million in Q4 2025, and $24.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | 12.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.75 Mn |
| Dec 31, 2025 | 22.20 Mn |
| Sep 30, 2025 | 24.47 Mn |
| Jun 30, 2025 | 25.16 Mn |
| Mar 31, 2025 | 22.99 Mn |
| Dec 31, 2024 | 21.24 Mn |
| Sep 30, 2024 | 26.84 Mn |
| Jun 30, 2024 | 24.70 Mn |
| Mar 31, 2024 | 39.14 Mn |
| Dec 31, 2023 | 21.47 Mn |
| Sep 30, 2023 | 20.65 Mn |
| Jun 30, 2023 | 19.91 Mn |
| Mar 31, 2023 | 19.37 Mn |
| Dec 31, 2022 | 15.27 Mn |
| Sep 30, 2022 | 12.95 Mn |
| Jun 30, 2022 | 13.85 Mn |
| Mar 31, 2022 | 32.29 Mn |
| Dec 31, 2021 | 29.66 Mn |
| Sep 30, 2021 | 8.32 Mn |
| Jun 30, 2021 | 9.53 Mn |